Pennsylvania Patent of the Month – September 2023

Mitochon Pharmaceuticals, Inc. is harnessing the power of the mitochondria to treat debilitating conditions such as Amyotrophic Lateral Sclerosis (ALS), Atypical Parkinsonism, and Autism Spectrum Disorder (ASD). Their innovative approach involves administering a pharmaceutical composition of 2,4-dinitrophenol (DNP) to patients in need of treatment.

The company focuses their drug development on drugs that target the mitochondria. A surprising number of conditions and diseases have been linked to mitochondrial dysfunction. By correcting these dysfunctions, Mitochon is hoping to create a new world of disease modifying therapies.

The company has recently been granted a patent for their approach which has achieved efficacy due to the precise dosage of 2,4-dinitrophenol (DNP), ranging from about 0.001 mg/kg of body weight to about 5 mg/kg of body weight. This carefully calculated dosage has shown promise in mitigating the progression of various disorders.

In the case of ALS, Atypical Parkinsonism, and ASD, administering this pharmaceutical composition has demonstrated potential in providing relief and improving the quality of life for those suffering from these conditions. Atypical Parkinsonism subtypes like progressive supranuclear palsy (PSP), dementia with Lewy bodies, multiple system atrophy, and corticobasal degeneration (CBD) are among the targeted conditions.

Mitochon has paved the way for personalized treatment plans, offering unit doses ranging from 0.1 mg to 300 mg. This allows for tailored treatments based on individual patient needs, maximizing the effectiveness of the therapy.

The ultimate goal is to induce an increase in the expression of brain-derived neurotrophic factor (BDNF), a crucial player in neuronal development. Through their method, Mitochon Pharmaceuticals aims to pave the way for a future where these challenging diseases can be effectively managed, slowed, or even reversed.

The implications of this groundbreaking treatment extend to a myriad of neurological, neurodegenerative, autoimmune, developmental, and metabolic diseases. From Multiple Sclerosis to Alzheimer’s, Epilepsy to Rheumatoid Arthritis, this method holds promise in altering the trajectory of these conditions.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts